If you have been reading about Research material and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Freeze-dried solid, often hygroscopic |
| Solubility class | Freely soluble in water | Aqueous buffers used for stock solutions |
| Storage, dry powder | Minus 20 °C or colder | Recommended for long-term retention |
| Storage, solution | 2–8 °C or frozen | Avoid repeated freeze-thaw cycles |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity percentage plus mass confirmation |
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
The oil-drug emulsion must have low solubility with the polymer membrane to ensure that the drug will be carried throughout the system properly and be released at the proper time and location. When the proper emulsion is obtained, the drug should be uniformly dispersed throughout the entire internal cavity of the polymeric membrane.
=== Lawsuits === On 12 January 2016, Dow Pharmaceutical Sciences and Valeant Pharmaceuticals North America LLC filed a lawsuit against Taro USA and Taro Industries, an Israel-based corporation. The lawsuit was filed for infringement upon their Onexton patent, by Taro attempting to submit an abbreviated new drug application (ANDA) to the Food and Drug Administration (FDA) for its generic 3.75% benzoyl peroxide and 1.2% clindamycin phosphate topical gel. The court concluded that Taro was guilty of attempting to submit an ANDA patent request before the Onexton patent expired. Perrigo settled its patent litigation with Valeant and Dow.
In July 2015, Galloway endorsed Jeremy Corbyn's campaign in the Labour Party leadership election. He tweeted: "Congratulations to Jeremy Corbyn MP and good fortune in the labour leadership contest. If he wins it will change everything ..." He said that he would become a Labour Party member "pretty damn quick" if Corbyn was elected as leader. Less than a week after Corbyn became leader, a Labour spokeswoman told The Times: "George Galloway has not applied to rejoin the Labour party and he will not be receiving an invitation." Corbyn said in July 2015 that he was appalled at the tactics Galloway used while defending his seat against Naz Shah (Labour) during the general election. In December, Corbyn said that Galloway's readmission to the party was a decision not within his powers. In July 2016, Galloway endorsed Corbyn's campaign in the Labour Party leadership election. He said: "If Corbyn wins a big victory – and I think he will – then that should be, and it's important that it is, the final burial of Blair and Blairism." Following Ken Livingstone's much criticised comments in April 2016 concerning Adolf Hitler and Zionism, Galloway supported Livingstone's argument. Galloway disputed that Livingstone's comments were antisemitic. "The Israel lobby has just destroyed the Labour Party", he tweeted in May 2016. "It is an amazing achievement". The Respect Party "voluntarily deregistered" from the Electoral Commission on 18 August 2016.
Gutter oil, trench oil, sewer oil, hogwash oil and tainted oil (Chinese: 地沟油 / 地溝油; pinyin: dìgōu yóu, or 餿水油; sōushuǐ yóu) are Chinese slang terms primarily used in China and Taiwan to refer to recycled oil. It can be used to describe the illicit practice of restaurants reusing cooking oil that has already been cooked for longer than safety codes permit. It can also be used to describe the reprocessing of yellow grease collected from sources such as restaurant fryers, kitchen waste, slaughterhouse waste and sewer drains. Since 2011, the Chinese government has significantly cracked down on the reuse of gutter oil for human consumption, with the Chinese government also implementing clearer regulations for dealing with waste oil. Selling gutter oil in China can result in lengthy prison sentences or the death sentence with reprieve. For example, in 2014, businessman Zhu Chuanfeng was sentenced to the latter for selling gutter oil. That same year, a major gutter oil scandal was uncovered in Taiwan. In 2015, Yeh Wen-hsiang, who was the chairman of a Taiwanese food company, was sentenced to 22 years imprisonment and fined NT$50 million (US$1.6 million) for selling 243 tonnes of gutter oil.
Sources: en.wikipedia.org
Under the new instructions, domestic media organizations were told not to report the locations or number of Pakistani airstrikes. On 17 March, the General Directorate of Intelligence (GDI) warned local media outlets not to report casualties among Taliban forces from Pakistani airstrikes, saying that doing so could have serious consequences. Afghan Media Support Organization (AMSO) reported that the Taliban had imposed extensive restrictions on the media, including censorship of security-related events, and restrictions on reporting Taliban casualties. It said that journalists had been forced to publish pro-Taliban reports, including during the border clashes with Pakistan, and that their online activities were being monitored.
=== Modification === Genital modification may be for aesthetic, medical or cultural reasons. This includes female genital mutilation (FGM), sex reassignment surgery (for trans men as part of transitioning), intersex surgery, and genital piercings. Use of anabolic steroids by bodybuilders and other athletes can result in significant enlargement of the clitoris along with other masculinizing effects on their bodies. Abnormal enlargement of the clitoris may be referred to as clitoromegaly or macroclitoris, but clitoromegaly is more commonly seen as a congenital anomaly of the genitalia. Clitoroplasty, a sex reassignment surgery for trans women, involves the construction of a clitoris from penile tissue. It is usually done alongside other feminizing surgeries, such as vaginoplasty. People taking male hormones or other medications as part of a gender transition usually experience dramatic clitoral growth; individual desires and the difficulties of phalloplasty (construction of a penis) often result in the retention of the original genitalia with the enlarged clitoris as a penis analog (metoidioplasty). However, the clitoris cannot reach the size of the penis through hormones. A surgery to add function to the clitoris, such as metoidioplasty, is an alternative to phalloplasty that permits the retention of sexual sensation in the clitoris.
=== Augmentation === Physicians often add a medication with a different mode of action to bolster the effect of an antidepressant in cases of treatment resistance; a 2002 large community study of 244,859 depressed Veterans Administration patients found that 22% had received a second agent, most commonly a second antidepressant. Stephen M. Stahl, renowned academician in psychopharmacology, has stated resorting to a dynamic psychostimulant, in particular, d-amphetamine is the "classical augmentation strategy for treatment-refractory depression". However, the use of stimulants in cases of treatment-resistant depression is relatively controversial. It is also possible to use a benzodiazepine as to improve sleep without impairing the antidepressant response specially in patients presenting symptoms of insomnia and disturbed sleep. A randomized controlled trial found that the use of eszopiclone with fluoxetine resulted in a better remission rate. Addition of atypical antipsychotics when the patient has not responded to an antidepressant is also known to increase the effectiveness of antidepressant drugs, albeit at the cost of more frequent and potentially serious side effects.
Sources: en.wikipedia.org
=== Screening and characterization of amylase and cellulase activities in psychrotolerant yeasts === The authors of this study sought to determine which yeasts were metabolically active at lower temperatures and could therefore be used for colder industrial processes. They grew various yeasts on medium at different temperatures, then determined enzyme activity by separating proteins on a gel and fingerprinting the individual bands. Through database search they found the enzyme of interest and discovered two individual yeasts that had higher activity at lower temperatures.
Acral nevus (melanocytic nevus of acral skin, melanocytic nevus with intraepidermal ascent of cells) Amelanotic blue nevus (hypomelanotic blue nevus) Balloon cell nevus Bannayan–Riley–Ruvalcaba syndrome Becker's nevus (Becker's melanosis, Becker's pigmentary hamartoma, nevoid melanosis, pigmented hairy epidermal nevus) Benign melanocytic nevus (banal nevus, common acquired melanocytic nevus, mole, nevocellular nevus, nevocytic nevus) Blue nevus (blue neuronevus, dermal melanocytoma, nevus bleu) Blue nevus of Jadassohn–Tièche (common blue nevus, nevus ceruleus) Carney complex (LAMB syndrome, NAME syndrome) Cellular blue nevus Centrofacial lentiginosis Congenital melanocytic nevus Deep penetrating nevus Dysplastic nevus (atypical mole, atypical nevus, B-K mole, Clark's nevus, dysplastic melanocytic nevus, nevus with architectural disorder) Dysplastic nevus syndrome (B-K mole syndrome, familial atypical multiple mole–melanoma syndrome, familial melanoma syndrome) Ephelis (freckle) Epithelioid blue nevus Generalized lentiginosis Giant pigmented nevus (bathing trunk nevus, congenital nevomelanocytic nevus, garment nevus, giant hairy nevus, nevus pigmentosus et pilosus) Halo nevus (leukoderma acquisitum centrifugum, perinevoid vitiligo, Sutton nevus) Hori's nevus (acquired bilateral nevus of Ota-like macules) Inherited patterned lentiginosis in black persons Ink spot lentigo (sunburn lentigo) Laugier–Hunziker syndrome Lentigo simplex (simple lentigo) Malignant blue nevus Medium-sized congenital nevocytic nevus Melanoacanthoma Melanocytic tumors of uncertain malignant potential Moynahan syndrome Mucosal lentigines (labial and penile and vulvar melanosis, melanotic macules) Nevus of Ito (nevus fuscoceruleus acromiodeltoideus) Nevus of Ota (congenital melanosis bulbi, melanosis bulborum and aberrant dermal melanocytosis, nevus fuscoceruleus ophthalmomaxillaris, oculodermal melanocytosis, oculomucodermal melanocytosis) Nevus spilus (speckled lentiginous nevus, zosteriform lentiginous nevus) Partial unilateral lentiginosis (segmental lentiginosis) Peutz–Jeghers syndrome Pigmented spindle cell nevus (pigmented spindle cell tumor of Reed, pigmented variant of Spitz nevus) Pseudomelanoma (recurrent melanocytic nevus, recurrent nevus) PUVA lentigines Small-sized congenital nevocytic nevus Spitz nevus (benign juvenile melanoma, epithelioid and spindle cell nevus, Spitz's juvenile melanoma) Solar lentigo (lentigo senilis, liver spot, old age spot, senile freckle)
MDMA is an entactogen or empathogen, as well as a stimulant, euphoriant, and weak psychedelic. It is a substrate of the monoamine transporters (MATs) and acts as a monoamine releasing agent (MRA). The drug is specifically a well-balanced serotonin–norepinephrine–dopamine releasing agent (SNDRA). To a lesser extent, MDMA also acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). MDMA enters monoaminergic neurons via the MATs and then, via poorly understood mechanisms, reverses the direction of these transporters to produce efflux of the monoamine neurotransmitters rather than the usual reuptake. Induction of monoamine efflux by amphetamines in general may involve intracellular Na+ and Ca2+ elevation and PKC and CaMKIIα activation. MDMA also acts on the vesicular monoamine transporter 2 (VMAT2) on synaptic vesicles to increase the cytosolic concentrations of the monoamine neurotransmitters available for efflux. By inducing release and reuptake inhibition of serotonin, norepinephrine, and dopamine, MDMA increases levels of these neurotransmitters in the brain and periphery and thereby indirectly activates the receptors of these neurotransmitters. There are species differences in the balance of MAT activities of MDMA, with it showing greater influence on serotonin in rodents than in humans. In addition to its actions as an SNDRA, MDMA directly interacts with a number of monoamine and other receptors.
Sources: en.wikipedia.org
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.
Reverse-phase liquid chromatography is used to assess purity, and mass spectrometry confirms molecular mass. Together these two checks form the most widespread approach. Some laboratories add amino acid analysis for further verification.
Yes. The peptide is freely soluble in water and in aqueous buffers, so reconstitution does not require an organic solvent. Stock solutions are usually prepared in water or a mild buffer. Exact handling depends on the intended downstream application.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.